Catch Up on the Latest News and Media Releases from Syndicate Bio
Syndicate Bio and SOPHiA GENETICS, a cloud-native healthcare software company known for pioneering data-driven medicine, have joined forces to facilitate the implementation of MSK-ACCESS® powered by SOPHiA DDM™ in Nigeria and Africa. Syndicate Bio is the first lab in Africa to embrace MSK-ACCESS® and the first company to make comprehensive genomic profiling and liquid biopsy widely available to patients throughout the entire continent.
Read MoreSyndicate Bio has entered into a Memorandum of Understanding with the National Institute of Cancer Research and Treatment (NICRAT), Nigeria's premier institution for cancer research, treatment, and control. Their collaborative initiative focuses on studying the most common cancers in Nigeria, providing valuable insights into their genomic profiles to enhance diagnosis, treatment, and support clinical and pre-clinical research.
Read MoreSyndicate Bio has signed a significant Memorandum of Understanding with Nigeria's leading research institution, the Nigerian Institute of Medical Research, paving the way for transformative genomic studies in infectious and non-infectious diseases and drug discovery in Nigeria.
Read MoreAt the recently concluded Women of Color in Pharma Inaugural Global Summit, our CEO, Dr. Abasi Ene-Obong, delivered a presentation titled ‘The Value Proposition for Doing Business on the Continent.'
Read MoreAt the 2023 World Health Summit, our Co-founder and Chief Scientific Officer, Dr Jumi Popoola, delivered a presentation on the ‘Use of predictive genomics to drive healthcare in resource-limited settings.’
Read More
